Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Integra Lifesciences ( (IART) ).
At its 2025 Annual Meeting of Stockholders on May 9, Integra LifeSciences announced the approval of an amendment to its equity incentive plan, increasing the number of shares available for awards by 2,200,000. Additionally, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year and approved executive compensation on an advisory basis. The Board also announced the transition of Dr. Stuart M. Essig from Executive Chairman to non-executive Chairman, effective July 1, 2025, with no disagreements cited regarding company operations.
The most recent analyst rating on (IART) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.
Spark’s Take on IART Stock
According to Spark, TipRanks’ AI Analyst, IART is a Neutral.
Integra Lifesciences faces significant challenges with declining profitability and negative valuation metrics. While there are areas of growth, such as revenue and instruments portfolio, the negative operating cash flow, increased ship holds, and tariff impacts present substantial risks. The technical analysis indicates bearish momentum, adding to the cautious outlook. Overall, the stock’s score reflects these mixed signals and the need for improvement in profitability and operational efficiency.
To see Spark’s full report on IART stock, click here.
More about Integra Lifesciences
Integra LifeSciences Holdings Corporation operates in the medical technology industry, focusing on the development and marketing of products used in neurosurgery, reconstructive, and general surgery. The company is known for its innovative solutions that enhance patient care and improve surgical outcomes.
Average Trading Volume: 983,986
Technical Sentiment Signal: Sell
Current Market Cap: $1.06B
For a thorough assessment of IART stock, go to TipRanks’ Stock Analysis page.